Status | Study |
Withdrawn |
Study Name: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas Condition: Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cel Date: 2010-12-16 Interventions: Drug: Ofatumumab Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks |
Active, not recruiting |
Study Name: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Condition: Follicular Lymphoma Marginal Zone Lymphoma Small Lymphocyt Date: 2010-11-10 Interventions: Drug: ofatumumab Weekly infusion for 8 weeks Other N |
Active, not recruiting |
Study Name: Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma Condition: Leukemia Lymphoma Date: 2009-08-20 Interventions: Drug: Bortezomib Starting dose |
Completed |
Study Name: Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Condition: Lymphoma, Non-Hodgkin Date: 2009-07-30 Interventions: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody) For the treatment of 1st or 2nd |
Active, not recruiting |
Study Name: Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Condition: Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplas Date: 2009-07-08 Interventions: Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell |
Withdrawn |
Study Name: Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Condition: Immunocytoma/Morbus Waldenström B-Cell Non-Hodgkin's Lymphoma Date: 2009-06-23 Interventions: Drug: Cyclophosphamide, Pentostatin, Rituximab |
Completed |
Study Name: High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas Condition: B-cell Lymphoma Indolent B-cell Lymphoma Date: 2009-05-06 Interventions: Drug: rituximab Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosi |
Terminated |
Study Name: A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Condition: Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, B-Cell Date: 2008-10-06 Interventions: Drug: AEG35156 antisense IV infusion AEG35156 will be give |
Completed |
Study Name: Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma Condition: B-cell Chronic Lymphocytic Leukemia Extranodal Marginal Zone B-cell Lymphoma of Mucosa-assoc Date: 2008-02-21 Interventions: Biological: therapeutic autologous lymphocytes |
Active, not recruiting |
Study Name: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Condition: Leukemia Date: 2007-04-25 Interventions: Biological: therapeutic autologous lymphocytes |